A Practical Guide for Medical Device Manufacturers

Introduction

Post-Market Clinical Follow-up (PMCF) has become one of the most important—and often misunderstood—requirements under the EU Medical Device Regulation (MDR). Many manufacturers still view PMCF as an optional activity or something only required for high-risk devices. In reality, MDR has fundamentally changed this perspective.

PMCF is no longer an “extra” step. It is a core part of the clinical evaluation lifecycle, and manufacturers are expected to either conduct PMCF or provide a strong, well-documented justification for not doing so.

This blog explains when PMCF is mandatory, what triggers it, and how manufacturers can approach PMCF strategically.

What Is PMCF?

PMCF is a continuous process of collecting and evaluating clinical data after a device has been placed on the market.

Its purpose is to:

• Confirm safety and performance in real-world use
• Identify previously unknown risks
• Monitor long-term outcomes
• Ensure the benefit–risk profile remains acceptable

PMCF is not separate from clinical evaluation—it is an extension of it. It feeds directly into the Clinical Evaluation Report (CER) and the overall post-market surveillance (PMS) system.

Is PMCF Mandatory Under MDR?

The short answer is:

Yes—unless you can justify why it is not required.

Under MDR, PMCF is expected as a proactive and continuous activity. Manufacturers must:

• Plan PMCF as part of PMS
• Conduct PMCF activities where necessary
• Or clearly justify why PMCF is not needed

This means the burden of proof has shifted. Instead of asking “Do we need PMCF?”, manufacturers must ask:

“Do we have enough clinical evidence to justify not conducting PMCF?”

Key Triggers for PMCF

PMCF becomes mandatory when there are clinical uncertainties or evidence gaps that cannot be fully addressed through pre-market data.

1. Limited Pre-Market Clinical Evidence

If the clinical data available before market entry is limited, PMCF is required to fill those gaps.

This may include situations where:

• Clinical investigations have small sample sizes
• Data is short-term
• Evidence is based mainly on literature or equivalence
• Certain subpopulations are underrepresented

In such cases, PMCF helps confirm whether the device performs as expected in real-world conditions.

2. Novel Technology or Mechanism of Action

Devices that introduce new or innovative technology often carry higher uncertainty.

Examples include:

• New materials
• New chemical or biological mechanisms
• New modes of action
• Innovative device designs

Because these devices lack extensive clinical history, PMCF is needed to monitor how they behave in real-world use.

3. High-Risk Devices

For Class III and implantable devices, PMCF is generally expected as part of ongoing safety and performance evaluation.

These devices:

• Have a higher risk profile
• May have long-term effects
• Require continuous clinical validation

Even when pre-market data is strong, PMCF is often necessary to confirm long-term outcomes and identify rare adverse events.

4. Uncertainty in Long-Term Outcomes

Pre-market studies often have limited duration. However, many clinical risks only become visible over time.

PMCF is required when there is uncertainty related to:

• Long-term safety
• Device durability
• Recurrence rates
• Late complications
• Cosmetic outcomes (where relevant)

PMCF provides real-world evidence that helps confirm whether early clinical results remain valid over time.

5. Residual Risks Identified in Risk Management

If the risk management process identifies residual risks, PMCF may be required to monitor them.

For example:

• Known side effects that require further observation
• Risks that cannot be fully mitigated pre-market
• Risks that depend on user behavior or real-world conditions

PMCF acts as a tool to verify whether these risks remain acceptable during actual use.

6. Reliance on Clinical Equivalence

When a manufacturer relies on clinical equivalence rather than direct clinical investigation data, PMCF may be required to confirm that the assumed equivalence holds true in practice.

This is particularly important when:

• Access to equivalent device data is limited
• Differences exist between devices
• Transferability of data is uncertain

PMCF helps bridge the gap between assumed and observed clinical performance.

When PMCF May Not Be Required

Although PMCF is widely expected, it may not be necessary in every case.

Manufacturers may justify the absence of PMCF when:

• The device is well-established
• Clinical data is extensive and robust
• Long-term safety and performance are well documented
• Risks are fully understood and controlled
• There are no significant uncertainties

However, this justification must be:

• Clearly documented
• Scientifically supported
• Based on a thorough clinical evaluation

A weak or generic justification is unlikely to be accepted.

Common Misconceptions About PMCF

“PMCF is only for high-risk devices”

While high-risk devices almost always require PMCF, lower-risk devices may also require it if clinical uncertainties exist.

A. “PMCF is optional”

Under MDR, PMCF is expected unless justified otherwise. It is not optional in the traditional sense.

B. “PMCF is a one-time activity”

PMCF is an ongoing process. It evolves as new data becomes available and as the device is used in broader clinical settings.

C. “PMCF is only about clinical studies”

PMCF can include various activities, such as:

• PMCF clinical investigations
• Registries
• Real-world data collection
• Literature updates
• User feedback and surveys

The approach depends on the level of uncertainty and risk.

Strategic Approach to PMCF

A strong PMCF strategy should be:

1. Risk-Based

The intensity of PMCF should match the level of risk and uncertainty.

2. Proportionate

Not all devices require complex studies. PMCF activities should be appropriate to the device.

3. Integrated

PMCF should be aligned with:

• Clinical evaluation
• Risk management
• PMS system

4. Proactive

PMCF should not be treated as a reactive exercise. It should be planned early and updated regularly.

How PMCF Supports Regulatory Success

A well-designed PMCF plan can:

• Strengthen clinical evidence over time
• Support ongoing compliance
• Reduce regulatory risks
• Improve confidence in device safety and performance
• Provide valuable real-world insights

Instead of viewing PMCF as a burden, manufacturers should see it as an opportunity to continuously validate and improve their device.

Key Takeaways

• PMCF is expected under MDR unless clearly justified otherwise
• It becomes mandatory when clinical uncertainties or data gaps exist
• Key triggers include limited data, novel technology, high risk, and long-term uncertainty
• PMCF is a continuous, risk-based process—not a one-time activity
• Strong justification is required if PMCF is not conducted

Final Thoughts

Under the EU Medical Device Regulation (MDR), clinical evidence does not stop at market entry—it continues throughout the device lifecycle.

PMCF reflects this shift.

It ensures that manufacturers remain accountable for the real-world safety and performance of their devices, not just their initial approval.

The real question is no longer:

“Is PMCF mandatory?”

But rather:

“Can we confidently demonstrate safety and performance without it?”

In most cases, PMCF is not just a regulatory requirement—it is a critical component of a robust and future-ready clinical strategy.